• Busca personas
• Intranet

Miogenesis, inflamación y función muscular Joaquim Gea

Publicaciones 2024 (24)

• Kawano-Dourado L^*, Kulkarni T, Ryerson CJ, Rivera-Ortega P, Guedes B, Chaudhuri N, Funke-Chambour M, Hoffmann-Vold AM, Johannson KA, Khor YH, Montesi SB, Piccari L, Prosch H, Molina-Molina M, Sellares J, Bauer-Ventura I, Rajan S, Jacob J, Richards D, Spencer LG, Wendelberger B, Jensen T, Quintana M, Kreuter M, Gordon AC, Martinez FJ, Kaminski N, Cornelius V, Lewis R, Adams W, Jenkins G, REMAP-ILD consortium. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases. Thorax 2024: (en Premsa).
• Bernabeu-Mora R, Oliveira-Sousa SL^*, Medina-Miralpeix F, Gacto-Sánchez M, Group of Investigation SAQ_COPD (...,Gea J,...). Identifying COPD patients with poor health status and low exercise tolerance through the five-repetition sit-to-stand test and modified Medical Research Council Dyspnea Score. Eur J Intern Med 2024: (en Premsa).
• Tomás-Pérez M^*, Trisán-Alonso A, Montoro-Ferrer A, Domínguez-Ortega J, Galindo-Bonilla PA, Clar-Castelló M, Naves JE, Ausin P. Concomitant Efficacy of Dupilumab in Treating Eosinophilic Esophagitis and Type 2 Asthma. J Invest Allergol Clin Immunol 2024: (en Premsa).
• Barreiro E^*, Gea J. Muscle Fatigability of Patients With Severe COPD and Chronic Respiratory Failure: The Contribution of Respiratory Factors. Arch Bronconeumol 2024: (en Premsa).
• Rodríguez-Chiaradia DA^*, Rodó A, Espina-Gonzalez C, Caballero-Rabasco MA, Ausin P, Sancho A, Preckler J, Admetllo M, Marco E, García J. Diagnosis and Management of Exercise-induced Laryngeal Obstruction (EILO): Initial Results of a Multidisciplinary Team. Arch Bronconeumol 2024: (en Premsa).
• Peracaula M, Sebastian L, Francisco I, Bonnin-Vilaplana M, Rodríguez-Chiaradia DA, Tura-Ceide O^*. Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment. Biomedicines 2024; 12(9): 1936.
• Casadevall C^*, Quero S, Millares L, Faner R, Cosío BG, Peces-Barba G, Castro-Acosta AA, Montón C, Palou A, Pascual S, Agustí A, Gea J, Monsó E, On Behalf Of The Biomepoc Group. Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD: A Pilot Study. Int J Mol Sci 2024; 25(15): 8467.
• Enriquez-Rodriguez CJ^*, Casadevall C, Faner R, Pascual S, Castro-Acosta AA, López-Campos JL, Peces-Barba G, Seijo L, Caguana OA, Monsó E, Rodríguez-Chiaradia DA, Barreiro E, Cosío BG, Agustí A, Gea J^*, On Behalf Of The Biomepoc Group. A Pilot Study on Proteomic Predictors of Mortality in Stable COPD. Cells 2024; 13(16): 1351.
• Vigil Gimenez L^*, Martínez-Llorens JM, Portillo-Carroz K, García-García R, Ortega Ruíz F, Puente-Maestu L, en representación del Grupo de Trabajo. [National Survey on the Activity of Lung Function Laboratories. Effects During the SARS-COV-2 Pandemic]. Open Respir Arch . 2024; 6(2): 100315 (Acceptat).
• Enriquez-Rodriguez CJ, Pascual S, Casadevall C, Caguana OA, Rodríguez-Chiaradia DA, Barreiro E, Gea J^*. Proteomic Blood Profiles Obtained by Totally Blind Biological Clustering in Stable and Exacerbated COPD Patients. Cells 2024; 13(10): 866.
• Josa-Culleré A, Basagaña X, Koch S, Arbillaga A, Balcells E, Bosch de Basea M, Celorrio N, Foraster M, Rodríguez-Roisín R, Marin A, Prado-Peralta G, Rodríguez-Chiaradia DA, Simonet P, Torán P, Vall-Casas P, Garcia-Aymerich J^*. Short-term effects of air pollution and weather on physical activity in patients with chronic obstructive pulmonary disease (COPD). Environ Res 2024; 247: 118195.
• Piccari L, Kovacs G, Jones S, Skaara H, Roca-Herms C, Bacchini -Jeanneret GS, Calzado M, Gonzalez-Rojas N, Fernández-Delgado M, Galvez-García HG, Schwicker D^*. The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments. Pulm Circ . 2024; 14(2): 12405 (Acceptat).
• Caguana OA, Khilzi K, Piccari L, Rodríguez-Sevilla JJ, Badenes D, González-Garcia J, Chalela R, Arita M, Rodó A, Herranz A, Admetllo M, Villar-García J, Molina L, Zuccarino F, Gea J, Balcells E, Rodríguez-Chiaradia DA^*. Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2. Respiration 2024; 103(2): 79-87.
• Piccari L, Wort SJ^*. Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?. Thorax 2024; 79(4): 295-296.
• Delgado-Ortiz L, Ranciati S, Arbillaga A, Balcells E, Buekers J, Demeyer H, Frei A, Gimeno-Santos E, Hopkinson NS, De Jong C, Karlsson N, Louvaris Z, Palmerini L, Polkey MI, Puhan MA, Rabinovich RA, Rodríguez-Chiaradia DA, Rodríguez-Roisín R, Toran-Montserrat P, Vogiatzis I, Watz H, Troosters T, Garcia-Aymerich J^*. Real-world walking cadence in people with COPD. ERJ Open Res 2024; 10(2): 00673-2023 (Acceptat).
• Enriquez-Rodriguez CJ, Casadevall C, Faner R, Castro-Costa A, Pascual S, Seijó L, López-Campos JL, Peces-Barba G, Monsó E, Barreiro E, Cosío BG, Agustí A, Gea J^*, BIOMEPOC group. COPD: systemic proteomic profiles in frequent and infrequent exacerbators. ERJ Open Res 2024; 10(2): 00004-2024 (Acceptat).
• Perez-Vizcaino F^*, Barberá JA, Rodríguez-Chiaradia DA. Vitamin D and Pulmonary Arterial Hypertension. Arch Bronconeumol 2024; 60(3): 131-132.
• Piccari L. Endothelial dysfunction in chronic obstructive pulmonary disease and its impact on gas exchange. Universitat de Barcelona. Director: Barbera JA, Blanco I. Fecha lectura: 21/02/2024.
  Cites:0
• Piccari L^*, Kaminski N, Mann ME. Fossil Industry and Respiratory Societies - Time for a Clear Stand. Am J Respir Crit Care Med 2024; 209(3): 245-247.
• Bertran-Recasens B, Balañá A, Martínez-Llorens JM, Guillén A, Villatoro M, García-Escobar G, Umayahara Y, Soh Z, Tsuji T, Rubio MA^*. Sound-based cough peak flow estimation in patients with neuromuscular disorders. Muscle Nerve 2024; 69(2): 213-217.
• Shlobin OA^*, Shen E, Wort SJ, Piccari L, Scandurra JA, Hassoun PM, Nikkho SM, Nathan SD. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. Pulm Circ . 2024; 14(1): e12310 (Acceptat).
• Margaritopoulos GA^*, Proklou A, Trachalaki A, Badenes D, Kokosi M, Kouranos V, Chua F, George P, Renzoni EA, Devaraj A, Desai S, Nicholson AG, Antoniou KM, Wells AU. Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortality. ERJ Open Res 2024; 10(1): 00740-2023 (Acceptat).
• Cano-Jiménez E^*, Villar-Gómez A, Vélez-Segovia E, Aburto-Barrenechea M, Sellares J, Francesqui J, Portillo-Carroz K, Solis-Solis AJ, Acosta-Fernández O, Llanos-González AB, Bordas-Martinez J, Cabrera-Cesar E, Balcells E, Castillo D, Reyes-Pardessus A, González-Fernández C, García-Moyano M, Urrutia-Gajate A, Blanco-Hortas A, Molina-Molina M. Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study. ERJ Open Res 2024; 10(1): 00405-2023 (Acceptat).
• Cullivan S, Boucly A, Jevnikar M, Lechartier B, Ulrich S, Bertoletti L, Sitbon O, Vonk-Noordegraaf A, Bokan A, Park DH, Genecand L, Guiot J, Jutant EM, Piccari L, Lichtblau M^*. ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2024; 10(1): 00847-2023 (Acceptat).